Latest Ratios: P/E Ratio 25.6x · EV/EBITDA 10.0x · ROE 5.6%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $17.6B | $17.9B | $21.5B | $25.5B | $26.8B | $25.9B | $30.9B | $30.0B | $20.5B | $23.8B | $20.3B |
| Enterprise Value | $24.5B | $24.8B | $27.2B | $30.9B | $32.1B | $32.6B | $38.3B | $37.6B | $28.9B | $33.5B | $30.9B |
| P/E Ratio → | 25.60 | 25.33 | 23.84 | 24.94 | 115.91 | 64.52 | — | 26.55 | — | 12.96 | 66.75 |
| P/S Ratio | 2.14 | 2.17 | 2.80 | 3.45 | 3.86 | 3.80 | 5.05 | 3.76 | 2.58 | 3.06 | 2.64 |
| P/B Ratio | 1.42 | 1.41 | 1.73 | 2.04 | 2.23 | 2.05 | 2.54 | 2.42 | 1.82 | 2.03 | 2.10 |
| P/FCF | 11.94 | 12.13 | 18.85 | 21.50 | 25.13 | 19.25 | 28.32 | 25.41 | 12.92 | 16.72 | 14.00 |
| P/OCF | 10.36 | 10.53 | 14.36 | 16.14 | 20.87 | 17.30 | 25.69 | 18.93 | 11.72 | 15.07 | 12.42 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.01 | 3.54 | 4.18 | 4.63 | 4.78 | 6.25 | 4.71 | 3.64 | 4.29 | 4.03 |
| EV / EBITDA | 9.98 | 10.10 | 11.93 | 13.85 | 19.80 | 18.14 | 38.99 | 17.55 | 26.88 | 17.97 | 16.59 |
| EV / EBIT | 17.99 | 22.07 | 21.69 | 24.34 | 56.54 | 46.11 | 357.99 | 33.21 | 1586.38 | 42.36 | 40.91 |
| EV / FCF | — | 16.84 | 23.82 | 26.01 | 30.11 | 24.21 | 35.03 | 31.85 | 18.22 | 23.46 | 21.33 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.6% | 61.6% | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% | 71.8% | 71.4% | 72.7% | 68.9% |
| Operating Margin | 16.5% | 16.5% | 16.7% | 17.3% | 10.0% | 12.6% | 1.4% | 14.3% | 0.4% | 10.2% | 10.7% |
| Net Profit Margin | 8.6% | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% | -2.3% | 14.2% | -4.8% | 23.2% | 4.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.6% | 5.6% | 7.2% | 8.4% | 1.9% | 3.2% | -1.1% | 9.6% | -3.3% | 16.9% | 3.1% |
| ROA | 3.2% | 3.2% | 4.2% | 4.8% | 1.0% | 1.7% | -0.6% | 4.6% | -1.5% | 6.9% | 1.1% |
| ROIC | 5.4% | 5.4% | 5.4% | 5.4% | 2.8% | 3.3% | 0.3% | 4.3% | 0.1% | 2.9% | 3.1% |
| ROCE | 6.9% | 6.9% | 6.8% | 6.8% | 3.6% | 4.1% | 0.4% | 5.3% | 0.2% | 3.4% | 3.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.59 | 0.50 | 0.46 | 0.47 | 0.56 | 0.67 | 0.66 | 0.79 | 0.86 | 1.16 |
| Debt / EBITDA | 3.06 | 3.06 | 2.72 | 2.59 | 3.51 | 3.93 | 8.28 | 3.84 | 8.32 | 5.45 | 6.04 |
| Net Debt / Equity | — | 0.55 | 0.46 | 0.43 | 0.44 | 0.53 | 0.60 | 0.61 | 0.74 | 0.82 | 1.10 |
| Net Debt / EBITDA | 2.82 | 2.82 | 2.49 | 2.40 | 3.28 | 3.72 | 7.46 | 3.55 | 7.82 | 5.17 | 5.70 |
| Debt / FCF | — | 4.70 | 4.97 | 4.51 | 4.99 | 4.97 | 6.70 | 6.44 | 5.30 | 6.74 | 7.33 |
| Interest Coverage | 3.84 | 3.84 | 5.76 | 6.30 | 3.45 | 3.39 | 0.50 | 4.99 | 0.06 | 2.43 | 2.13 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | 1.98 | 1.91 | 1.61 | 1.88 | 1.41 | 1.99 | 1.37 | 1.83 | 1.49 | 1.96 |
| Quick Ratio | 1.10 | 1.10 | 0.99 | 0.78 | 0.97 | 0.79 | 1.03 | 0.68 | 0.90 | 0.81 | 1.14 |
| Cash Ratio | 0.23 | 0.23 | 0.21 | 0.15 | 0.16 | 0.11 | 0.31 | 0.18 | 0.22 | 0.17 | 0.27 |
| Asset Turnover | — | 0.36 | 0.36 | 0.34 | 0.33 | 0.29 | 0.25 | 0.32 | 0.33 | 0.30 | 0.29 |
| Inventory Turnover | 1.38 | 1.38 | 0.98 | 0.87 | 0.94 | 0.91 | 0.74 | 0.94 | 1.01 | 1.02 | 1.21 |
| Days Sales Outstanding | — | 75.58 | 70.38 | 71.20 | 72.66 | 67.34 | 86.53 | 62.37 | 58.70 | 72.23 | 76.37 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.1% | 1.1% | 0.9% | 0.8% | 0.8% | 0.8% | 0.6% | 0.7% | 1.0% | 0.8% | 0.9% |
| Payout Ratio | 27.0% | 27.0% | 21.7% | 19.6% | 86.9% | 49.8% | — | 17.4% | — | 10.7% | 61.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.9% | 3.9% | 4.2% | 4.0% | 0.9% | 1.5% | — | 3.8% | — | 7.7% | 1.5% |
| FCF Yield | 8.4% | 8.2% | 5.3% | 4.7% | 4.0% | 5.2% | 3.5% | 3.9% | 7.7% | 6.0% | 7.1% |
| Buyback Yield | 2.8% | 2.7% | 4.0% | 2.7% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% |
| Total Shareholder Yield | 3.8% | 3.8% | 4.9% | 3.5% | 1.2% | 0.8% | 0.6% | 0.7% | 1.0% | 0.8% | 3.0% |
| Shares Outstanding | — | $199M | $204M | $210M | $210M | $210M | $207M | $207M | $204M | $204M | $202M |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZBH stock.
Zimmer Biomet Holdings, Inc.'s current P/E ratio is 25.6x. The historical average is 31.4x. This places it at the 59th percentile of its historical range.
Zimmer Biomet Holdings, Inc.'s current EV/EBITDA is 10.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.4x.
Zimmer Biomet Holdings, Inc.'s return on equity (ROE) is 5.6%. The historical average is 19.4%.
Based on historical data, Zimmer Biomet Holdings, Inc. is trading at a P/E of 25.6x. This is at the 59th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Zimmer Biomet Holdings, Inc.'s current dividend yield is 1.05% with a payout ratio of 27.0%.
Zimmer Biomet Holdings, Inc. has 61.6% gross margin and 16.5% operating margin. Operating margin between 10-20% is typical for established companies.
Zimmer Biomet Holdings, Inc.'s Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Goodwill impairment and leverage
Metrics are mathematically derived from official filings.
Deep Value Discount to Peers
ZBH trades at 10.5x EV/EBITDA versus Stryker's 23.8x and Medtronic's 14.9x, per recent market data, implying the market prices in minimal growth despite mid-single-digit revenue expansion.
The forward P/E of 11.46 is dramatically below the sector average, suggesting the market is skeptical of earnings quality or growth durability. The EV/EBITDA multiple of 10.52 is roughly half of Stryker's, indicating a value-oriented pricing that may not fully reflect ZBH's stable cash generation. Investors should monitor whether the discount narrows as operating margins stabilize.
Margin Volatility Masks Core Stability
Gross margin averaged 71% over the last ten quarters, but operating margin swung from 12.8% to 19.2%, per SEC filings, indicating that cost control and one-time items drive profitability more than pricing power.
The 2025Q4 gross margin dip to 64.7% appears to be an anomaly, as it recovered to 70.8% in 2026Q2. Net margin has ranged from 6.2% to 13.7%, reflecting significant quarterly noise. The stable gross margin suggests the core business is resilient, but operating leverage is inconsistent, warranting a focus on SG&A efficiency.
Subdued Returns on Invested Capital
ROIC has remained below 2% for the past ten quarters, per financial statements, while ROE hovers around 1-2%, indicating that the company is not compounding returns on its large asset base.
With goodwill representing 43% of total assets, the return on capital is diluted by acquisition-related intangibles. The low ROIC relative to peers like Stryker (11.1%) suggests that ZBH's capital allocation has not generated commensurate returns. This may reflect integration challenges or a competitive market, and investors should monitor whether new product cycles improve asset efficiency.
Working Capital Drags on Cash Flow
Cash conversion cycle averaged 391 days over the last ten quarters, per reported figures, driven by high inventory days (DIO) of 354-424 days, indicating significant capital tied up in inventory.
DSO has been stable around 70 days, but DIO is exceptionally high, suggesting either slow-moving orthopedic products or deliberate inventory builds. The CCC of 376 days in 2026Q1 is a major drag on free cash flow, though FCF margin improved to 32.9% in 2026Q2. This inefficiency may be a competitive disadvantage versus more agile peers.
Leverage Creeps Higher, Coverage Thins
Debt-to-EBITDA rose from 9.5x in 2024Q4 to 22.8x in 2026Q2, per balance sheet data, while interest coverage fell to 4.5x, indicating a deteriorating debt service capacity.
The D/E ratio has increased from 0.46 to 0.59 over the period, and the spike in D/EBITDA in 2026Q2 is alarming, though it may be distorted by quarterly EBITDA volatility. Interest coverage of 4.5x is still adequate but down from 6.9x in 2024Q2. The company's cash position has thinned to $410M, which could limit flexibility if earnings weaken.
Liquidity Buffer Thins Rapidly
Current ratio fell from 2.44 in 2025Q1 to 1.69 in 2026Q2, while cash dropped to $410M, per recent filings, indicating a tighter liquidity position that may strain under stress.
The quick ratio has been volatile, dipping to 0.63 in 2024Q2, suggesting that inventory is a significant component of current assets. With cash declining and debt rising, the company's ability to weather a downturn without accessing capital markets appears reduced. Investors should monitor whether the current ratio stabilizes above 1.5.
Misapplied EV/EBITDA Multiple
The EV/EBITDA ratio is commonly misapplied to ZBH because its EBITDA is inflated by large non-cash charges, per financial statements, obscuring true cash earnings power.
Given the high DIO and significant working capital needs, EBITDA overstates cash generation. A more appropriate metric is EV/EBIT or EV/FCF, which better captures the capital intensity. For instance, EV/FCF would be higher than EV/EBITDA, reflecting the drag from inventory. Investors should adjust for working capital changes when comparing ZBH to asset-light peers.